Project Grant K43TW012859

Award Date 9/1/24
Completion Date 8/31/29
Dollars Obligated $99K
Federal Grant Program
93.989
Assistance Type
Project Grant
Place of Performance
Tanzania
Similar Awards
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $186,319 to The Regents of the University of California, San Francisco (UCSF) to adapt and test an intervention to reduce HIV-related stigma among pregnant and postpartum women in sub-Saharan Africa. The key activities include: 1) Describing the stigma experiences and mental health impacts of women living with HIV during...
This Project Grant award from the National Institute of Mental Health (NIMH) under CFDA 93.242 - Mental Health Research Grants provides $185,040 to the University of Southern California to pilot test and evaluate a "total school approach" to addressing HIV-related stigma and discrimination in Zambian boarding schools. The project aims to co-create stigma reduction intervention packages with key stakeholders and train learners, teachers, and staff to deliver trainings to at least 80% of...
This $196,881 Project Grant was awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) to adapt and pilot test an intervention to reduce alcohol use and improve HIV care outcomes among men living with HIV who have serodiscordant pregnant partners in Uganda. The overarching goal is to adapt the KISOBOKA intervention, which utilizes motivational interviewing and behavioral economics techniques, for use with this target...
This $3,067,394 Project Grant from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a 2-year research study to test a peer-driven "intravention" approach to address unmet harm reduction needs among people who use drugs in two rural Kentucky counties. The project, titled "Engaging People Who Use Drugs in Harm Reduction Service Delivery", aims to reduce the risk of overdose, hepatitis C, skin/soft tissue...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), is intended to develop and pilot a telehealth intervention delivered through syringe service programs (SSPs) to improve uptake and retention of pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD) among racially and regionally diverse people who inject drugs (PWID) in Minnesota. The $239,148 award, with a project period...
This $375,000 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to evaluate the impact of a status-neutral, person-centric intervention called the "Blue Shed" on HIV transmission and outcomes among people who inject drugs (PWID) in New Delhi, India. The project has three key objectives: Assess the direct impact of the Blue Shed intervention on HIV incidence, viral suppression, and mortality among PWID...
This federal Project Grant award, with ID R01TW012908, was provided by the Fogarty International Center (CFDA 93.989) under the "International Research and Research Training" program. The $185,273 grant will fund a project to adapt and pilot an intervention to reduce HIV/AIDS and drug use stigma and increase retention in HIV care among women living with HIV who use drugs in Ukraine. The key project activities include: 1) Adapting a small group, multi-session intervention to train...
This $1,192,612 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to integrate HIV prevention services into clinical care settings for people with opioid use disorder (OUD). The key objectives are to: 1) conduct a systematic assessment of healthcare utilization, HIV prevention services, and medication for OUD (MOUD) using claims and emergency department data; 2) use an evidence-based quality improvement...
This federal Project Grant award of $709,872 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop and pilot test a couple-based intervention to address perinatal depression and improve adherence to prevention of mother-to-child transmission (PMTCT) of HIV in Malawi. The key objectives are to: 1) develop a couple-based intervention using problem-solving therapy and content on couple...
The National Institute on Drug Abuse (NIDA) awarded a $873,784 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Arizona State University to develop and pilot-test "Project Vuselela", an intervention integrating peer navigation and family engagement to improve antiretroviral therapy (ART) adherence and opioid substitution therapy (OST) continuation among people who inject drugs in South Africa. The project aims to assemble evidence-based practices,...

ADAPTING EVIDENCE-BASED STIGMA REDUCTION INTERVENTIONS TO ADDRESS HIV AND DRUG USE STIGMA AMONG FAMILY MEMBERS OF PEOPLE WHO USE DRUGS - PROJECT SUMMARY THE BURDEN OF HIV AMONG PEOPLE WHO USE DRUGS (PWUD) IS HIGH IN TANZANIA. NO CURRENT NATIONAL DATA ARE AVAILABLE IN TANZANIA ON THE BURDEN OF DRUG USE AND HIV AMONG ALL PWUD. A STUDY CONDUCTED IN 2017 IN DAR ES SALAAM, A BUSINESS CAPITAL OF TANZANIA, INDICATED HIV PREVALENCE OF 8.7% AMONG A SAMPLE OF PEOPLE WHO INJECT DRUGS (PWID) WHICH IS ROUGHLY TWICE AS HIGH AS HIV PREVALENCE IN THE GENERAL POPULATION (4.7%). ONE OF THE CHALLENGES OF THE EFFORTS TO CONTROL HIV AMONG PWUD GLOBALLY INCLUDING TANZANIA IS HIV AND DRUG USE STIGMA. PWUD FACE DIFFERENT KINDS OF HIV AND DRUG USE STIGMA GLOBALLY AND IN TANZANIA. THESE STIGMAS HAVE NEGATIVE PHYSICAL AND MENTAL HEALTH OUTCOMES FOR PWUD AND ARE A BARRIER TO GENERAL HEALTH CARE AND HIV PREVENTION, CARE AND TREATMENT. THERE IS GROWING RECOGNITION OF THE NEED TO ADDRESS HIV AND DRUG USE STIGMA FACED BY PWUD--YET RESEARCH AND INTERVENTIONS TO DO SO ARE LIMITED. INTERVENTIONS TO ADDRESS HIV AND DRUG USE STIGMA FROM HEALTH CARE WORKERS TOWARDS PATIENTS EXIST BUT NOT WITH FAMILIES. A FAMILY IS CRITICAL TO SUPPORT PWUD TO ENTER AND REMAIN IN HIV AND DRUG PREVENTION AND TREATMENT PATHWAYS. ALSO REDUCING FAMILY STIGMA IS CRUCIAL TO IMPROVE QUALITY OF LIFE OF PATIENTS. IN SPITE OF THIS, GLOBALLY THERE ARE NO INTERVENTIONS TO ADDRESS HIV AND DRUG USE STIGMA FROM FAMILY MEMBERS TOWARDS PWUD. TO ADDRESS THIS GAP, I PROPOSE TO ADAPT EXISTING EVIDENCE-BASED HEALTH FACILITY HIV AND DRUG USE STIGMA REDUCTION INTERVENTIONS AND CREATE A STIGMA-REDUCTION INTERVENTION FOR FAMILY MEMBERS OF PWUD THAT WILL ADDRESS BOTH HIV AND DRUG USE STIGMA COMING FROM FAMILY MEMBERS GOING TOWARDS PWUD. THEREFORE, THE SPECIFIC AIMS OF THIS STUDY ARE TO: 1. ADAPT EXISTING HEALTH FACILITY HIV AND DRUG USE STIGMA REDUCTION INTERVENTIONS TO ADDRESS HIV AND DRUG USE STIGMA AMONG FAMILY MEMBERS OF PWUD IN TANZANIA. 2. ASSESS THE ACCEPTABILITY, FEASIBILITY, APPROPRIATENESS, ADOPTION, AND FIDELITY OF THE ADAPTED FAMILY HIV AND DRUG USE STIGMA REDUCTION INTERVENTION AMONG FAMILY MEMBERS OF PWUD IN TANZANIA. 3. DETERMINE PSYCHOMETRIC PROPERTIES OF DEVELOPED HIV AND DRUG USE STIGMA MEASURES. METHODS: WE WILL ACHIEVE SPECIFIC AIM 1 THROUGH A STEP-WISE ADAPTATION PROCESS STARTING WITH THE FORMATIVE ASSESSMENT. WE WILL CONDUCT IN-DEPTH INTERVIEWS WITH 36 PWUD WHO ARE ABOUT TO START METHADONE TREATMENT AND THOSE WHO ARE ON MAT IN THE FIRST SIX MONTH AND 36 FAMILY MEMBERS OF PWUD TO DETERMINE THE RELATIONSHIPS, TYPES AND MANIFESTATIONS OF HIV AND DRUG USE STIGMA THAT PWUD FACE FROM FAMILY MEMBERS TO INFORM WHAT AND HOW TO ADAPT THE INTERVENTION AND IMPLEMENTATION. PRINCIPAL INVESTIGATOR (PI) AND STIGMA EXPERTS WILL USE THE RESULTS OF THE FORMATIVE ASSESSMENT TO CREATE DRAFT 1 CURRICULUM OF THE INTERVENTION. PWUD, THEIR FAMILY MEMBERS, KEY STAKEHOLDERS AND TOPICAL EXPERTS WILL BE INVOLVED TO REVIEW DRAFT 1. STIGMA EXPERTS AND THE PI WILL INTEGRATE FEEDBACK TO CREATE DRAFT 2 OF THE INTERVENTION CURRICULUM. WE WILL ACHIEVE SPECIFIC AIM 2 BY IMPLEMENTING THE INTERVENTION AMONG 151 FAMILY MEMBERS OF PWUD USING DRAFT 2 OF THE INTERVENTION CURRICULUM. AFTER THE IMPLEMENTATION, WE WILL MEASURE THE IMPLEMENTATION OUTCOMES NAMELY ACCEPTABILITY, FEASIBILITY, APPROPRIATENESS, ADOPTION, AND FIDELITY USING MIXED METHODS. ONE FOCUS GROUP DISCUSSION (FGD) WILL BE DONE FROM EACH OF THE TEN GROUPS OF FAMILY MEMBERS THAT RECEIVED THE INTERVENTION. ALL PARTICIPANTS WILL BE SURVEYS AND 6-8 PARTICIPANTS SELECTED RANDOMLY FOR FGDS. TO ADDRESS SPECIFIC AIM 3, WE WILL USE SECONDARY DATA AVAILABLE FROM OUR PREVIOUS GRANT (1R21TW011786) TO DETERMINE THE PSYCHOMETRIC PROPERTIES (VALIDITY AND RELIABILITY) OF EXPERIENCED, ANTICIPATED, PERCEIVED, AND INTERNALIZED HIV AND DRUG USE STIGMA MEASURES. WE WILL CONDUCT EXPLORATORY AND CONFIRMATORY FACTOR ANALYSES, AND KNOWN-GROUP VALIDITY ANALYSES.

Posted 8/5/24, 12:00 AM